Therefore, to contribute to the discovery of novel anti-osteoporosis agents, we identified KCB-F06 as a novel Keap1–Nrf2 PPI inhibitor that showed anti-osteoclastogenic activity in vitro and blocked OVX-mouse bone loss in vivo. Here, NFE2L2 is linked to osteoporosis.